Lexeo Therapeutics
LXEO
90 hedge funds and large institutions have $194M invested in Lexeo Therapeutics in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 30 increasing their positions, 11 reducing their positions, and 8 closing their positions.
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
173% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 11
30% more funds holding
Funds holding: 69 → 90 (+21)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.68% less ownership
Funds ownership: 89.94% → 89.26% (-0.68%)
28% less capital invested
Capital invested by funds: $269M → $194M (-$74.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$4.54M |
| 2 |
ACM
Altium Capital Management
New York
|
+$3.19M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.99M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$2.76M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$9.23M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$6.59M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.89M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.06M |
| 5 |
DCP
D1 Capital Partners
New York
|
-$2.38M |
LXEO Hedge Fund Activity: Q4 2024 in Review
90 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q4 2024, worth a combined $194M — down 28% from $269M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new LXEO positions and 8 closed out — a net gain of 21 holders — while 30 added to existing stakes and 11 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $4.54M. The largest seller was Omega Fund Management, cutting an estimated $9.23M.
- 90 institutional investors held Lexeo Therapeutics (LXEO) as of Q4 2024, up from 69 in Q3 2024.
- Funds reported $194M of Lexeo Therapeutics stock for Q4 2024, down 28% quarter-over-quarter.
- 29 funds opened new Lexeo Therapeutics positions in Q4 2024 and 8 closed out, a net change of +21 holders.
- The largest Lexeo Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $4.54M added.
- The largest Lexeo Therapeutics seller in Q4 2024 was Omega Fund Management, an estimated $9.23M sold.
Based on aggregated 13F filings for Q4 2024.